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The cost-of-illness (COI) analysis [1] is the first and most commonly used
method of health monetary assessment for evaluating the economic impact
of a disease on the society, with regard to both the consumption of health
resources and productivity losses.
Although some COI studies were carried before the 1960s, the fundamen-
tals of the COI methodology were described in detail for the first time in the
work of Dorothy Rice in the United States [2]. Since then, many data on the
cost of diseases have been published for several countries. However, there
are still debates on the reliability and validity of this methodology among
the insiders. A few years later the Rice’s work, Hodgson and Meiners [3] pro-
vided detailed guidelines for undertaking COI studies, which still continue
to be the most cited in works where technical methods are at issue.
The main criticisms raised by economists are that COI studies are not
based on welfare economic theories and that other forms of economic assess-
ment (i.e. cost-effectiveness and cost-benefit analyses) could be more useful
for decision-makers.
On the contrary, COI studies, if considered as descriptive analyses, can
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represent an excellent economic tool to inform decision-makers and to sup-
port the political process and the management functions at different levels
of health organizations [4].
To be effective, a COI study should make it possible to measure the true
cost for the society, to estimate the main cost components and their impact
on the total cost, and to explain their variability.
1.1 Disease-specific and general COl studies
COI analyses have been classified in two main categories, disease-specific
and general studies [5], even if literature is mostly represented by the first
ones. In the disease-specific COl studies, all costs relevant to the disease
of interest are combined to obtain an estimate of the total cost. To ful-
fil this purpose, patient-based information on healthcare consumption and
productivity losses, and the corresponding unit prices, are used (bottom-up
approach). Such studies can have a cross-sectional or longitudinal design.
While the former is based on data regarding the expenditures of the dif-
ferent cost components in a given year, the longitudinal approach provides
estimates of the lifelong expenditures by following patients over time.
General COI studies have a cross-sectional design and are aimed at de-
scribing the overall economic impact of all the diseases classified in the Inter-
national Classification of Diseases (ICD), in a given year. As the diseases are
aggregated into major categories, much broader disease definitions are used
than in disease-specific studies. General COI studies are usually based on
aggregated data on healthcare utilization obtained from national registries
and other official sources (top-down approach) [6].
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1.2 Prevalence- versus incidence-based COI studies
COI studies can be based on incidence or prevalence [7,8].
Prevalence-based COI studies provides estimates of the economic burden of
a disease in a predefined period of time, usually a year, by quantifying the
value of the resources used by all cases (both prevalent and incident) during
that time. On the other hand, incidence studies evaluate the lifetime costs
attributable to the new cases of a disease, who had their onset in a given
period. The main difference between these two methodologies [7] is that,
while under the prevalence approach both the direct and the productivity
costs due to the disease are assigned to the year in which they occurred, the
principle of the incidence study is to evaluate and assign all the costs to the
year in which the disease made its debut [8,9].
The cost estimates obtained by applying the two different approaches are
different when chronic conditions are considered, the estimates computed
under the prevalence approach being generally greater than those computed
under the incidence approach.
Disease-specific studies can be based either on prevalent or incident cases,
while general studies are always cross-sectional and, therefore, based on
prevalent cases. The prevalence-based approach is more appropriate if an
estimate of the cost components or cost containment policies within a lim-
ited period of time are needed. Indeed, this approach provides decision
makers with a picture of the global burden and of the main components of
current healthcare expenditure, where cost containment policies would have
the greatest impact [4].
If, on the other hand, the objective is to make decisions about the choice
of which treatment or public health strategy should be adopted to obtain
the maximum effectiveness, the incidence method is more appropriate as it
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makes possible to obtain predictions of the possible cost savings deriving
from programs that can reduce the incidence and improve the health status.
The incidence approach is also useful to evaluate the cost distribution dur-
ing illness progression and it allows the development of clinical/therapeutic
guidelines aimed at increasing the effectiveness and the efficiency of the dis-
ease management and of each single step of the clinical therapeutic pathway
[6].
1.3 Top-down versus bottom-up approaches
A top-down analysis is performed in general COI studies "from the top-
down", allocating portions of a known total expenditure obtained at the
national level to each of several broad disease categories. On the contrary,
both the prevalence and incidence approaches in disease-specific COI studies
require a "from the bottom-up" procedure for collecting input data. Under
the bottom-up approach [6], variables are measured at the individual level
and costs are calculated by multiplying the quantity of healthcare services
used and the amount of productivity losses that each subject reported, by
their unit costs.
1.4 Prospective versus retrospective COI studies
Incidence-based COIs can be prospectively or retrospectively performed
depending on the temporal relationship between the start of the study and
data collection.
Whilst in retrospective COI analyses all relevant events have already oc-
curred at the beginning of the study, in prospective COI studies the relevant
events have not yet occurred when the study starts. Prospective COI studies
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imply that data are collected by following-up the patients over time and can
only be carried out when sufficient data are available, but this is not often
the case as data could have been collected for different purposes from those
of a COI study.
Retrospective COIs are especially effective to investigate chronic diseases
with a long duration and they are less expensive and time consuming than
those performed prospectively because all relevant events have already oc-
curred at the time the study is initiated. Vice versa, under a prospective
COI approach, it is possible to plan data collection, for example by designing
ad hoc questionnaires to be answered by patients. This allows, for example,
to obtain complete data even for those cost components that are usually not
registered by the healthcare organizations [6].
1.5 Cost components
The quantifiable economic burden of a disease is typically divided into
two major cost components: "core costs" are those directly resulting from
the illness and "other disease-related costs" include non-healthcare costs due
to the disease. Within each category, we can identify direct and indirect costs
[10].
Direct costs are those for which payments are made and refer to the
healthcare costs associated with medical expenses for the diagnosis and treat-
ment of a disease, and to the non-healthcare costs related to the consumption
of other resources (e.g. the time dedicated by family members or volunteers
to the patients care, or to their transport to and from health providers).
Indirect costs, also known as productivity costs, are those for which re-
sources are lost and consist in cessation or reduction of work productivity
due to illness or death [11]. Indirect costs are therefore associated with mor-
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bidity and mortality and can be further classified as absenteeism (withdrawal
from work) or presenteeism (inefficiency in work due to impairment) [12].
The indirect costs can also be calculated by evaluating the leisure time
forgone as a result of illness. Despite this cost component is rarely considered
in applied studies, it has a huge value to individuals. The parameter of mon-
etization of leisure time forgone is given by the net salary that an individual
could receive if he/she were employed. An alternative way to evaluate the
loss of productivity is therefore to refer to the remuneration of an individual
employed in an activity similar to that of the unpaid worker or to consider
the wage of part-time help as replacement value.
Some medical and non-medical cost items (for example the costs associ-
ated with home care or to the pain and psychological distress of patients)
are difficult to classify into the classic cost components and for this reason
are often defined as "other indirect costs".
Although these "other indirect costs" represent an important part of the
total cost attributable to the disease [13,14], they are rarely considered in
COI studies because they are hardly quantifiable in monetary terms.
1.6 Human Capital Approach
Under the Human Capital Approach (HCA) it is possible to estimate
the productivity costs due to morbidity and mortality, assuming that the
expected future earnings reflect the potential contribution of the individual
to the economy, or more precisely, that a worker’s salary is equivalent to the
value of his marginal product.
Although its basic principles were known at least since the seventeenth
century [15], the HCA approach was developed mainly at the beginning of the
1960s, a period in which economists have focused more on human resources,
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until then neglected and underestimated in the US economy [16].
As suggested by Mushkin [17], wages and salaries are paid in exchange
for a direct return on services and therefore they correspond to the actual
individual contribution to production. In COI analyses, morbidity indirect
costs are estimated multiplying average wages by the number of working
days lost and the number of days with reduced efficiency at work in the
reference period. Instead, mortality indirect costs measure the lost produc-
tivity (i.e. number of working days) due to premature death in the reference
period. For some categories outside the labor market such as housewives,
the "replacement value approach", which estimates the services provided on
the basis of their corresponding market value, is used. Another approach is
the "opportunity cost", which assumes that the economic value of unpaid
work is at least equal to the wage that the same person should have on the
market [18,19]. However, this approach is inconsistent with that used on the
working population, which is assessed on the actual work carried out, rather
than on what could be done [8].
Similarly, people who were too sick to work or keeping house were consid-
ered as following the same labor force experience as the general population.
Therefore, it is assumed that if these people had entered the labor market,
the employment rate and the level of earnings would not have diminished.
Given the high rates of unemployment, it could be also supposed that peo-
ple suffering from chronic illnesses, even if they were no longer ill, would
probably not have worked anyway and therefore should not be considered
in the calculation of productivity costs. Both positions are extreme because
assuming a situation of full employment is not realistic even in a period of
economic growth and, in the same way, the hypothesis of non-employment
for chronically ill patients (even if no longer sick) is too pessimistic. At this
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point a solution could be to apply the national unemployment rate to those
patients who are too ill to work, albeit potentially in the active labor force,
and to assume that the production losses refer only to the remaining part of
the patients.
Other health economists [21-26] also questioned the reliability of the HCA
in estimating production losses due to the disease. In fact, it is believed that
the HCA overhangs the indirect costs in an economy with less than full
employment.
In general, production losses can result from short- and long-term work
absences.
For short-term absences, a person’s work can be covered by others or
compensated by the patient on his return to work, thus representing a cost
to the individual but not to society.
The time required to replace a sick worker or to reorganize the pro-
duction process, called the attrition period, depends on the availability of
qualified personnel within companies, the labor market and the level of un-
employment. As a result, productivity costs are directly proportional to the
duration of this period.
1.7 Willingness-to-Pay Approach
The COI studies conducted under the HCA approach represent an ex-
cellent tool for providing decision makers with an assessment of the current
allocation of resources.
However, HCA does not aim to estimate the economic value of human
life but it only attempts to measure the loss to society deriving by disease
morbidity and mortality that cause persons to lose time from work and other
productive activities. Indeed, the HCA approach measures the lost wages
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not considering the individuals’ willingness to pay (WTP) to reduce the risk
of getting ill.
In contrast, WTP makes it possible to evaluate the change in defensive
expenditures and to overcome the problem of incorporating non-monetary
information on quality of life into the economic calculus [27]. Therefore, by
providing a comprehensive estimate of the value attached to a reduction in
risk of illness, WTP quantifies the intangible costs that conversely remain
rather intractable with the HCA approach.
1.8 Role of the cost-of-illness studies in health eco-
nomics
Undoubtedly, COI studies are a very important decision-making tool and
play a key role in health economics. The criticisms made by economists about
the fact that COI studies are far from fully representing the welfare economy,
and the need to make them more reliable by includingWTP techniques [28] in
the computations of intangible costs, are fundamentally based on the serious
mistake that arises from considering them as a sort of cost-benefit analysis
(CBA). The COI analysis is essentially a descriptive study that differs from
all other types of economic evaluation, as it does not compare the costs with
the results, and that could assume an enormous value if considered from the
right perspective.
The principal aim of a COI analysis is to evaluate the economic burden
of a disease for society. Therefore, COI studies succeeding in quantifying the
resource utilization due to an illness may allow the classification of diseases
according to their global burden, along with epidemiological data on their
morbidity and mortality.
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Another great advantage of this type of analysis is the possibility of
quantifying the main cost components and assessing their impact on the to-
tal cost. This is of fundamental importance in the field of health policies as
they enable decision makers both to focus interventions on cost items that
have a greater impact on the total cost and to evaluate the effectiveness of
previously adopted health policies. The evidence obtained from COI studies
may represent the basis for the redesign of individual medical services or
of entire therapeutic models that have proved ineffective, enabling the dis-
ease clinical management to be improved and optimized through targeted
interventions.
A further strong point of this approach is that it makes possible to es-
timate the variability of costs determined by factors related to the disease
(e.g. severity), to the patient (e.g. demographic characteristics) or to the
services providing health care (e.g. hospital centers). An assessment in this
sense would provide decision-makers with very useful detailed information
in order to plan the provision of health services in a tailored way.
To achieve these objectives, COI studies should therefore be conceived





According to the Global Initiative for Asthma (GINA) international
guidelines on the disease management and prevention [29], asthma is a
chronic disease of the airways characterized by (i) a more or less accessory
bronchial obstruction usually reversible spontaneously or following therapy,
(ii) bronchial hyperreactivity and (iii) an accelerated decline in respiratory
function that may evolve, in some cases, into an irreversible airway obstruc-
tion. Bronchial asthma is therefore defined as a pathology characterized
by peculiar clinical, physiological and pathological aspects. The infiltration
of inflammatory cells, the release of mediators and the airways remodeling
constitute the main pathogenetic mechanisms of the disease [30]. In asthma,
inflammation is present even if the symptoms are episodic and the correlation
between asthma severity and the intensity of inflammation has not yet been
established. The inflammatory reaction causes a variable obstruction of the
airways, rupture of the epithelium, infiltration in the airways of eosinophils
and lymphocytes, vasodilation and finally remodeling of the airways, with
trophic variations such as hyperplasia and hypertrophy of the smooth mus-
cle, vascular neoformation, increase in the number of epithelial goblet cells
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and deposit of interstitial collagen below the epithelium.
Asthma is the result of a complex interaction between the genetic and
environmental factors, and its pathogenesis is not entirely clear [31]. These
multiple factors interact with each other leading to a variable narrowing of
the airways. Since asthma can be configured with extremely different clinical,
biological and functional patterns, in recent years a new vision of the disease
has been consolidated, in which its heterogeneous character is emphasized.
The extreme heterogeneity of asthma allowed to identify different phenotypes
and endotypes of the disease, in which a specific pathogenetic mechanism
corresponds to a biological framework and to its consequent clinical manifes-
tations [32]. The characterization of the disease endotype mainly recognizes
two mechanisms underlying the inflammatory process: the activation of the
Th2 inflammatory cascade, implicated in the allergic pathogenesis, whose ac-
tivation will lead to the release of specific pro-inflammatory cytokines, with
the eosinophilic granulocyte as the final mediator of the inflammatory pro-
cess; and the Th1 mediated mechanism, which generally recognizes different
inducing factors (pollutants, smoke, viruses, etc.) and is characterized by a
different activation of the cytokine pattern, with the neutrophil granulocyte
as the ultimate effector. Airway remodeling is thought to be the mechanism
underlying the chronicity and progression of asthma. It is characterized by
structural alterations both at the level of the large and the small airways
and consists in the aberrant repair of the epithelium and in the accumu-
lation of myofibroblasts that contribute to the deposition of extra-cellular
matrix proteins and ultimately to the development of persistent bronchial
obstruction. The main structural alterations in remodeling are sub-epithelial
fibrosis, bronchial smooth muscle mass augmentation and angiogenesis.
From a clinical point of view, asthma is characterized by dyspnea, wheez-
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ing, coughing and a feeling of chest tightness; all these manifestations are
generally related to the extent of bronchial obstruction. Symptoms often
occur at night or early in the morning and can be perceived differently be-
tween individuals and during different stages of the disease. During asthma
attacks, patients generally have some characteristic clinical signs: cyanosis,
numbness, speech reduction, tachycardia, pulmonary insufflation, use of ac-
cessory muscles and retraction of intercostal muscles during breathing.
2.1 Asthma epidemiology
Asthma is one of the most common diseases in the world [33], it is present
in all countries but its prevalence varies considerably from nation to nation
and can also show differences within the same country. According to the
GINA guidelines [34], there are as many as 300 million people in the world
suffering from the disease, one in every 20, and over 30 million asthmatics in
Europe. The lack of a precise and unambiguous definition of asthma implies
the difficulty to precisely estimate the prevalence of this disease in the world.
However, through the application of standardized methods to measure the
prevalence of asthmatic symptoms in children and adults, it seems that the
global prevalence of asthma is between 1% and 18% of the population in
different countries.
In most European countries, the prevalence and the incidence of asthma
increased substantially between 1950 and 2000, but in the past decade, at
least in Western Europe, this increase has levelled off [35]. In general, in the
28 countries from the European Community, it was estimated that there are
more than 30 million of asthmatics (mean asthma prevalence of 7%), that
account for a total expense of more than EUR 20 billion in the European
population aged from 15 to 64 years [35].
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The prevalence trend in adults is still controversial: some studies suggest
stabilization or decrease, while others describe a further increase. However,
the stabilization of the prevalence trend seems to be due to the improvement
of anti-asthmatic treatments, and the incidence plateau seems to be due
to the saturation phenomenon: the development of the disease has been
achieved in all susceptible subjects.
Unfortunately, few studies reported a reliable assessment of the trend of
asthma prevalence, as it requires repeated cross-sectional studies on different
occasions on the same population and the use of an identical study design
over an adequate period of time. A study with these characteristics [36],
carried out on the adult population of Italy, reported an increase of the
median prevalence of current asthma from 4.1% in 1990 to 6.6% in 2010.
According to a recent paper [37] that evaluated the rates of asthma inci-
dence and remission in Italy from 1940 to 2010, the rates of asthma incidence
linearly increased, with a percent-age increase of +3.9% (95%CI: 3.1-4.5),
from 1940 up to the year 1995 and underwent a substantial stabilization in
the late 90s. The stabilization of asthma incidence was explained by the
authors to be due to a decrease in the rates of atopic asthma after 1995,
while non-atopic asthma has continued to increase. This study also pointed
out that, despite remarkable improvements in the treatment of asthma, the
overall rate of remission (43.2/1000person-years) did not vary significantly
in the last seventy years in Italy.
The prevalence of asthma tends to be higher in northern and western na-
tions and, in general, in the developed compared to the developing countries
[38].
In the developed countries the prevalence is higher among the poorest
population, which probably has not a complete access to treatment, while
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in the developing countries it is higher in the richer population, probably
because of major differences in lifestyle (such as the different exposure to
allergens, the possibility of treating the most serious diseases). In addition,
the prevalence of asthma varies according to ethnic and racial differences,
linked to underlying genetic variants, and to socioeconomic and environmen-
tal factors.
The interaction mechanism between genetic and environmental factors
that causes the clinical manifestations of asthma is complex and not en-
tirely known. Individual risk factors (e.g. genes, obesity, sex) predispose the
individual to asthma [38]. Many genetic polymorphisms have been shown
to be involved in the pathogenesis of asthma with differences in various
ethnic groups. In particular, they are related to the production of allergen-
specific IgE (atopy), the expression of bronchial hyperreactivity, the pro-
duction of inflammation mediators and growth factors or the determination
of the Th1/Th2 ratio in the immune response. Male sex is a risk factor
for asthma in children, as the prevalence of asthma in males is about twice
that of females up to 14 years of age. Over lifetime the difference between
the sexes is reduced and in adulthood the prevalence of asthma is higher in
females. On the other hand, environmental factors (e.g. allergens, tobacco
smoking, occupational exposures, pollutants) may influence the possibility of
developing asthma in predisposed subjects, triggering exacerbations and/or
causing the persistence of symptoms. The relationship between allergen ex-
posure and the onset of asthma is not clear, in any case it depends on the type
of allergen, the dose, the exposure time, the age at the time of exposure and
genetic factors. Smoking is associated with an accelerated decline in lung
function in patients with asthma, may increase the severity of symptoms




Asthma can be classified according to its etiology and severity. Based
on etiology, classical differentiation is between extrinsic (allergic) asthma, in
which symptoms are triggered by an allergen (such as dust mites, pet dander,
pollen or mold), and intrinsic (non-allergic) asthma, which tends to start
later in life, is more common in females, and is typically more severe. Apart
from some clinical differences concerning the onset, the severity and the
natural history, the two forms are quite similar from a pathological, physio-
pathological and pharmacological point of view. However, it is important to
make an accurate etiological investigation for prevention purposes.
Instead, there are significant differences in terms of disease severity and
exacerbations. The classification of asthma severity proposed by the "World
Asthma Project" established by the National Heart, Lung and Blood Insti-
tute (NHLBI) and the World Health Organization (WHO) is based on the
combination of different types of characteristics, such as symptoms, respi-
ratory function and pharmacological dosage necessary for keeping asthma
under control. In clinical practice, a correct classification of severity is
needed for adapting treatment to the clinical needs of the asthmatic patient.
The fundamental difference is between intermittent asthma with occasional
episodes, which requires occasional treatment with symptomatic drugs, and
persistent asthma with close episodes, which requires a background treat-
ment with a dosage appropriate to the presence of a mild, moderate or
severe form [38]. Severity should be reassessed periodically, usually every
3 months. Patients with clinical-functional characteristics of severe asthma
require greater control because of the risk of fatal exacerbations. Asthmatic
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exacerbations are defined as a worsening of symptoms associated with acute
limitation of airway flow, due to inadequate treatment of a causal stimulus.
2.3 Asthma control
Asthma control is assessed on the basis of symptoms and the quality of
daily life. It also includes the probability of loss of control, exacerbations,
decreased respiratory function and side effects of treatment. The goal of
asthma treatment is to achieve and maintain control of clinical manifesta-
tions of the disease over prolonged periods. Asthmatic patients can achieve
various levels of asthma control, depending on several factors including dis-
ease severity, exposure to triggers, treatments and patient compliance. The
GINA network has established guidelines for the assessment and manage-
ment of asthmatic patients by health professionals. The GINA guidelines
[39] classify asthma control levels as "well controlled", "partially controlled"
and "uncontrolled", on the basis of daytime symptoms, night awakenings,
normal activities affected by symptoms, and relief inhalers use. However,
despite the GINA recommendations and other local guidelines, there is no
standard management protocol for asthmatic patients throughout Europe.
2.4 Asthma burden
According to the WHO [33] 4.3% of the global population of younger
adults aged 18-45 years, reported a doctor’s diagnosis of asthma, 4.5% re-
ported either a doctor’s diagnosis or that they were taking treatment for
asthma, and 8.6% reported that they had experienced attacks of wheezing
or whistling breath (symptoms of asthma) in the preceding 12 months. Aus-
tralia, Northern and Western Europe, and Brazil had the highest prevalence.
17
Because of its high prevalence among younger working age groups, evi-
dence suggests an upward trend of the per-patient costs mainly due to pro-
ductivity losses. Recently, several papers have been published on the eco-
nomic burden of asthma, but the estimates of the cost components generally
vary between different countries. This may depend in part by the fact that
while some studies included patients representative of all age groups [40-45],
others applied age cut-offs [13,46-49]. However, most of the differences be-
tween studies depend on the different study design adopted. Indeed, some
studies analyzed administrative health data [42-44,47,48,50] whereas others
were designed as survey-based studies. Administrative health data regularly
record the use of health resources but they generally consider only a limited
amount of cost items. On the other hand, survey-based studies [13,40,41,46]
may have a high degree of representativeness and external validity, but at the
same time they may suffer from recall bias, which can alter the estimates
of the burden. Nevertheless, a good agreement between self-reported and
administrative data was assessed in terms of direct costs.
Despite the asthma costs vary widely from country to country it was
estimated that the mean cost per patient per year is $USD 1,900 and $USD
3,100 in Europe and in USA, respectively [51].
With regard to cost components, literature reports that medication rep-
resent the major burden among direct costs both in North America and
Europe, ranging from 51% in the United States [42] to 68% in Canada,
and from 45% (Spain) to 84% (Germany) in 11 European countries during
1999-2002 [46]. Whilst cost of medications are increasing over time in the
United States and Canada [41,42,47], in the Middle-East and South-East
Asia, out-patient costs were responsible for a greater proportion of the total
costs [43,44,49]. Probably, this may be explained by the lack of access to
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the more expensive combination inhalers, which can result in higher rates of
poorly controlled asthma, causing frequent visits to care providers. In North
America the costs of in-patient care and of physician visits demonstrated
a decreasing trend [42,47], whilst one study reported that the costs of out-
patient visits and ED visits increased by 3% and 8%, respectively [41]. As
demonstrated by a review on the asthma burden, in general, the loss of work-
ing days represents a higher cost compared to direct costs [52]. Few studies
have reported information on the indirect costs of asthma and, among these,
the results vary widely between the various jurisdictions. The lowest and
highest estimates come from the same country (Republic of Korea) [44,48]
and this could be partly due to different definitions and measurement meth-
ods among the studies. Indeed, in the study with the highest estimated
indirect costs, all sources of productivity loss (work/school days lost, early
retirement and work absenteeism) have been considered.
Asthma can be a controllable condition in most patients [53]. Studies
that report data on the potential reduction in the costs of asthma when an
individual moves from uncontrolled to controlled status are useful from a
clinical and public health perspective. In fact, asthma exacerbations require
the consumption of healthcare resources and productivity losses, and there-
fore increase the economic impact of the disease. However, in order to assess
the association between the level of asthma control and costs, studies should
consider the effect of potential confounding variables, such as asthma sever-
ity and socio-economic status. Unfortunately, among the studies reporting
costs across different levels of asthma control [46,48,54-57], only few of them
used regression-based methods to derive an adjusted estimate of the impact
of the lack of control on the costs of the disease [54-56].
Two COI studies that evaluated the costs of asthma according to the
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degree of disease control and considering the effect of potential confounding
variables were published by Accordini et al in 2006 and 2013 [46,58]. The
first COI study was carried out on current adult asthmatics (20-44 years)
from the general population in Italy and demonstrated that asthma-related
costs were substantial even in unselected patients, were largely driven by
indirect costs and that about half of the total cost was due to a limited pro-
portion of poorly controlled asthmatics. The more recent study published
in 2013 by the same author, was conducted in adult patients (30-54 years)
with persistent asthma, who were identified in general population samples
from 11 European countries and examined in clinical settings in the Eu-
ropean Community Respiratory Health Survey II between 1999 and 2002.
This study demonstrated that among European adults, the cost of persis-
tent asthma drastically increases as disease control decreases suggesting that






COPD is one of the most common chronic and disabling inflammatory
diseases worldwide [59, 60]. It causes obstructed airflow from the lungs and
the related symptoms include breathing difficulty, cough, mucus (sputum)
production and wheezing. Most people with COPD have a combination of
both chronic bronchitis, which involves a long-term cough with mucus, and
emphysema, which involves damage to the lungs over time. COPD is caused
by the long-term exposure to irritating gases or particulate matter, most
often from cigarette smoke, and it increases with age. It is associated with
substantial morbidity and mortality. Indeed, subjects with COPD are at an
increased risk of developing heart disease, lung cancer and a variety of other
conditions.
The first objectives to pursue for a successful management of COPD are
to early diagnose the disease and to prevent its progression. The assessment
of COPD is based on a history of exposure to risk factors and the presence of
airflow limitation that is not fully reversible, with or without the presence of
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symptoms. Spirometry test represents the gold standard as it is the most re-
producible, standardized, and objective way of measuring airflow limitation.
In order to prevent the onset and progression of COPD an important goal
is the reduction of total personal exposure to occupational dusts and chemi-
cals, and indoor and outdoor air pollutants. In particular, smoking cessation
represents the single most effective and cost-effective way to reduce the risk
of developing COPD and to stop its progression. To effectively manage sta-
ble COPD, it should be adopted a stepwise increase in treatment, depending
on the severity of the disease. However, none of the existing medications for
COPD has been shown to modify the long-term decline in lung function and
bronchodilator medications (e.g. 2-agonists, anticholinergics, theophylline,
and a combination of one or more of these drugs) are used to decrease symp-
toms and complications. Exacerbations of respiratory symptoms requiring a
medical intervention are important clinical events in COPD and they can be
caused by an infection of the tracheobronchial tree and air pollution, though
the cause of about one-third of severe exacerbations cannot be identified.
Inhaled bronchodilators are the election treatment of exacerbations thought
patients with clinical signs of airway infection (e.g. increased volume and
change of color of sputum or fever) may benefit from antibiotic treatment.
Because of the heterogeneity and complexity of the disease, the con-
cept of endotypes (e.g. COPD with alpha-1-antitrypsin deficiency, persistent
pathogenic bacterial colonization or persistent systemic inflammation) was
introduced over the past few years, referring to patients’ subtypes defined
by a distinct pathophysiological mechanism. The correct identification of
the different subtypes of the disease could allow a targeted treatment and a
personalised management of patients. Within this complexity, a key role is
played by the typical coexistence of other medical conditions beside COPD
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that can worsen the severity of the disease in individual patients by increasing
both morbidity and mortality. Therefore, the management of COPD should
have a holistic approach considering the assessment and the treatment of
comorbidities along with the traditional pharmacological therapy focused on
treating chronic airflow limitation. Comorbidities commonly associated with
COPD are: cardiovascular diseases, skeletal muscle dysfunction, ostheoporo-
sis, psychological disturbances, gastro-oesophageal reflux disease, obstructive
sleep apnoea, diabetes/metabolic syndrome, renal insufficiency, lung cancer
and infections. It was estimated that up to 90% COPD patients can have at
least one of these comorbidities [61].
3.1 COPD definition and severity
So far, the published epidemiological studies on COPD are based on dif-
ferent definitions that consider either symptoms, a diagnosis made by a doc-
tor and/or spirometric data. The International Union against Tuberculosis
and Lung Disease and the European Community Respiratory Health Sur-
vey (ECRHS) provided questionnaires on respiratory health, which include
questions on the clinical definition of chronic bronchitis.
The most used spirometric definition of COPD is that recommended
by the Global Initiative for chronic Obstructive Lung Disease (GOLD),
which considers a post-bronchodilator Forced Expiratory Volume in 1 sec-
ond (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.70, whatever the
age and the sex of the patients [60]. However, multiple studies have shown
that the GOLD definition tends to overdiagnose COPD in the elderly as the
FEV1 value decreases more quickly with age than FVC. The international
Burden of Obstructive Lung Disease (BOLD) study suggested a definition
based on a FEV1/FVC ratio less than the lower limit of normal (LLN), and
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FEV1 either less than 80% or below the LLN. Using the LLN, based on
age- and sex-stratified pre-bronchodilator cut-off values of the FEV1/FVC
ratio, is one way to minimise the potential misclassification by considering
abnormal only the values lower than the 5th percentile of a healthy, non-
smoking population. Afterwards, the American Thoracic Society (ATS) and
the European Respiratory Society (ERS) recommended to replace the fixed
cut-off criterion (FEV1/FVC<0.70) with the LLN. As spirometry is the most
reproducible way of measuring airflow limitation and FEV1 is the variable
most closely associated with prognosis [62], the degrees of COPD sever-
ity are usually assessed according to FEV1. The GOLD guidelines catego-
rize airflow limitation for patients with FEV1/FVC<0.70 into four different
stages: mild (FEV1>=80% predicted), moderate (50%<=FEV1<80% pre-
dicted), severe (30%<=FEV1<50% predicted) and very severe (FEV1<30%
predicted), where the FEV1 predicted is defined as FEV1% of the patient
divided by the average FEV1 in the population for any person of the same
age, height, gender, and ethnic group.
Using data from a large cohort of young adults (20-44 years), followed for
nine years during the 1990s as part of the European Community Respiratory
Health Survey (ECRHS) I, Cerveri et al [63] demonstrated the importance of
using statistically derived spirometric criteria to identify airflow obstruction.
In this study, the LLN equations for young adults were obtained from the
normal non-smoking participants in the ECRHS I and clinical and functional
characteristics and longitudinal outcomes of the subjects identified as "nor-
mal" by the fixed ratio but abnormal by the LLN were investigated. The
authors showed that the 70% fixed cut-off identified less than 50% of young
subjects who had evidence of airflow obstruction using the LLN criteria.
In addition, a study published by de Marco et al in 2009 [64] determined
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that COPD was associated with poor long-term outcomes in smokers and in
symptomatic subjects only and suggested that definitions of COPD based
exclusively on the presence of airflow obstruction assessed by spirometry may
include a non-negligible percentage of subjects with no clinically relevant
disease (asymptomatic nonsmokers).
Different studies investigated whether the presence of chronic symptoms
can predict the future occurrence of COPD, after adjusting for the well-
known risk factors, such as smoking habits, giving contrasting results [65-67].
In order to test whether chronic cough/phlegm and dyspnea are indepen-
dent predictors of the subsequent occurrence of COPD, de Marco et al [68]
evaluated, using the GOLD staging system, the incidence of COPD in a co-
hort of young adults identified in 1991-1993 in the ECRHS I and reassessed
in 1999-2002 in the ECRHS II.
The results of this study showed that the incidence of COPD was sub-
stantial even in young adults and that the presence of chronic cough/phlegm
identified a subgroup of subjects with a high risk of developing COPD, in-
dependently of smoking habits.
3.2 COPD epidemiology
COPD is a complex and heterogeneous condition characterized by a huge
morbidity and mortality burden. Indeed, it is predicted that by 2020 it will
become the third leading cause of death accounting for over 6 million deaths
annually worldwide. The Global Burden of Disease Study [69] reported that
globally, from 1990 to 2015, the prevalence of COPD increased by 44.2%,
whereas age-standardised prevalence decreased by 14.7%.
Although the prevalence of COPD has been well studied, few population-
based studies investigated its incidence. Overall, studies reported a wide
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range in incidence rates varying between 2-16/1000PY depending on the
COPD definition being used and the population being studied [68,70-78].
From 1991 to 2002 the incidence of COPD in an international cohort of
young adults from 12 European countries, was 2.8 cases/1,000/yr (95% CI:
2.3-3.3) [68].
Afonso et al estimated that three out of 1000 subjects per year were
diagnosed with COPD in the Netherlands and that the incidence, higher in
men than in women, increased rapidly with age [79].
In addition, in a more recent prospective population-based cohort study
(Rotterdam Study) the overall incidence of COPD was 9.4/1000 PY, with a
higher incidence in males and in smokers [80].
However, it has been estimated that only 10-15% of all COPD cases
are identified. A study [81] conducted in the United Kingdom on 39,000
patients with a COPD diagnosis has shown the failure of physicians and
patients to recognise the significance of symptoms, which results in a missing
opportunity for an earlier diagnosis.
3.3 COPD burden
As for asthma, the costs of COPD vary largely in different regions of the
world.
Indeed, according to a recent review [82] the average total direct costs
of COPD per person-year range from $USD 536 to $USD 6,213 in North
America and from $USD 679 to $USD 2,865 in Europe. The same review
reported that the indirect costs of COPD per person-year range from $USD
227 to $USD 985 in North America and from $USD 124 to $USD 3,754 in
Europe.
This may depend on both an actual variability in COPD costs and on
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differences in costing methods. For example, a critical factor is represented
by the quantification of the economic impact of comorbid conditions. In
fact, a US study [83] showed a reduction in the estimate of direct costs
from $USD 6,213 to $USD 536 per patient in a year after the statistical
adjustment for demographic variables and 19 comorbidities. Though it is
difficult to discriminate COPD attributable costs from the costs due to co-
morbid conditions [84], it is also true that these conditions contribute to
the pathophysiological process of COPD and, therefore, should be included
in the computations of the COPD burden. In addition, as in the case of
asthma, the published studies on COPD costs vary substantially in terms
of patients’ age (i.e. working age groups [45,49] or younger adults [13,50])
or the methodological approach (i.e. population-based survey [18,49,50] or
administrative health data [83-88]). Moreover, fundamental differences be-
tween studies exist in the level of disease severity [14] (only patients with
moderate or with severe COPD) or duration [85,86] (i.e. patients with newly
diagnosed COPD). The above-mentioned factors, together with the fact that
COPD is often underdiagnosed in many countries, make difficult to compare




Chronic bronchitis is defined as an inflammation of the lining of the air-
ways leading to narrowing and obstruction, and resulting in daily cough with
sputum production that lasts for at least three months, two years in a row.
Although people of any age can develop chronic bronchitis, the majority of
people diagnosed with the disease are 45 years of age or older. Chronic bron-
chitis is characterised by the loss of the airway cell’s cilia, whose function is
to maintain the airways clear of particles and fluids, and their replacement
by goblet cells that secrete mucus into the airway. The mucus represents an
excellent medium for growing bacteria and often becomes infected causing
an inflammation that can significantly inhibit the airflow to and from the
lung alveoli by narrowing and partially obstructing the bronchi and bron-
chioles. The airway irritation can stimulate the muscles surrounding the
airways causing a bronchospasm that can result in further airway narrowing.
As chronic bronchitis is characterised by a long-standing inflammation, the
muscular spasm can result in a fixed, nonreversible narrowing of the airway,
namely COPD. Indeed, it is generally difficult to separate these conditions
as patients often have components of each disease. In chronic bronchitis, the
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fixed airway obstruction and inflammation can cause an impairment in the
blood oxygenation and in carbon dioxide removal. The main symptoms of
chronic bronchitis are cough and sputum production, dyspnea and wheez-
ing. If these symptoms worsen or become more frequent, they often require
antibiotics, an increase in respiratory inhaled medications or steroid treat-
ment. Chronic bronchitis is commonly caused by cigarette smoking or by
other inhaled repeatedly bronchial irritants. Though chronic bronchitis is a
progressive condition, it could often have a good prognosis for many years
if it is diagnosed before bronchial damage occurs and if risk factors (smok-
ing, exposure to airborne chemicals and secondhand smoke, dust, and other
bronchial irritants) are avoided.
The prevalence of chronic bronchitis and the distribution of its risk fac-
tors vary widely both across and within countries and most epidemiological
studies report chronic bronchitis data only in elderly people [89-91].
An European study (ECRHS) [92] carried out on 18,000 subjects aged
20-44 yrs evidenced that the median prevalence of chronic bronchitis was
2.6%. In addition, this study pointed out that the prevalence of chronic
bronchitis varies widely across countries (0.7-9.7%) and that only 30% of
this geographical variability in prevalence was explained by differences in
smoking habits, suggesting that other environmental and/or genetic factors




Despite in recent years literature on the socioeconomic burden of asthma
has increased, most studies derived their estimates from official statistics or
from clinically selected samples, which do not permit to evaluate the whole
range of disease severity and control. Most studies have been focused on
estimating average costs of asthma only in a defined period and they have
not analysed the trend of the socio-economic burden over time according to
the level of disease severity and control. In addition, very few COI analyses
are recent and have been carried out at an international level in the general
population in Europe on the differential costs of asthma and other respiratory
diseases. Furthermore, there is few information on the socio-economic burden
of chronic bronchitis, also in relation with the presence of comorbidities.
In order to investigate the mentioned points, the objectives of the present
thesis are:
• Study 1: Cost of asthma, COPD and chronic bronchitis
To evaluate the differential cost of asthma, COPD, and chronic bron-
chitis among adult subjects from the general population in Europe,
who were identified at the ECRHS III (2010-2013).
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• Study 2: Cost variations of asthma over ten years
To estimate the ten-year variation of asthma costs in the adult asth-
matics who were identified at the ECRHS II (1998-2002) and partici-




The ECRHS is the first international multi-centre survey of the preva-
lence, incidence, determinants and management of asthma and COPD in
the general young adult population. It started during the 1990’s in response
to the global increase in asthma prevalence observed during the previous
decades and, though it was originally designed to cover most areas of the
European Community, it also included other countries outside Europe. The
ECRHS used standardised protocols for physician-led interviews, the assess-
ment of atopy through skin prick tests and the measurement of serum specific
IgE to common allergens, lung function measurements, tests of airway hy-
perresponsiveness, and blood and urine collection.
Between 1991 and 1993, 56 centres from 25 countries across Europe and
other parts of the world took part in the first survey (ECRHS I) [93]. A
community-based random sample of young adults aged 20-44 was identified
from available population based registers and was invited to complete a short
postal screening questionnaire (stage 1). Between 1991 and 1994, a random
sample of the responders to the screening questionnaire was invited to attend
the local clinical centre (stage 2), where the selected subjects provided more
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detailed information on their health status and risk factors for asthma and
allergic disease (family history of disease, occupation, childhood and current
exposure to pets, exposure to tobacco smoke, dampness, ventilation, use of
soft furnishings and use of gas appliances). Blood samples were taken and
serum was tested for specific IgE to house dust mite, cat, grass and Cla-
dosporium herbarum. Pre-bronchodilator forced expiratory volume in one
second (FEV1) and forced vital capacity (FVC), and bronchial reactivity to
methacholine were measured. In addition, most centres enriched their ran-
dom sample with a symptomatic sample of the individuals who had reported
symptoms suggestive of asthma (being woken by breathlessness or asthma
attacks in the last 12 months) and/or current use of asthma medication, but
who had not been selected as part of the random sample at the screening
stage. Around 200,000 participants completed the screening questionnaire
(stage 1) and around 26,000 from 45 centres participated in the clinical stage
(stage 2).
Between 1998 and 2002, twenty-nine of the initial 56 study centres per-
formed a follow-up investigation (ECRHS II) [94]. All participants in the
clinical stage of the ECRHS I (from both the random and symptomatic
samples) were asked to take part in the ECRHS II. About 10,000 subjects
were assessed in the clinical centres, where detailed information on their
health status, risk factors, lung function tests and blood and urine samples
were collected. Fourteen centres from 6 European countries also agreed to
measure indoor and outdoor NO2 at the participants’ home using passive
diffusion samplers (Passam, AG, Switzerland).
Twenty-nine centres from 14 countries (mostly European) carried out a
further follow-up contact (ECRHS III). Individuals who had participated in
the clinical stage of the ECRHS I were sent a short screening questionnaire
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and, in 27 centres, those who responded were invited to a local clinical cen-
tre for a detailed interview, and for the assessment of lung function, FeNO,
venepunctures for specific and total IgE testing. ECRHS III [95] started
in 2010 and was completed in 2013 with over 6,000 participants from the
original random sample and over 900 participants from the original symp-




Study 1: Cost of asthma,
COPD and chronic bronchitis
7.1 Methods
7.1.1 Study participants
The study population was recruited from 26 centres in 12 European coun-
tries (Belgium, Denmark, Estonia, France, Germany, Iceland, Italy, Norway,
Spain, Sweden, Switzerland and the United Kingdom) and comprised adult
subjects (aged 39-68 years) who had participated in the ECRHS III. The
present study included 1,489 subjects with complete information on their
disease status and with information on the cost components due to their
illness. These patients were identified as having current asthma (n=781),
COPD (n=181) or chronic bronchitis (n=527). Ethical approval was ob-
tained for each centre from the appropriate ethics committee and written




The subjects with current asthma were those who had reported a physician
diagnosis of asthma during their life and at least one respiratory symptom
(wheezing, nocturnal tightness in the chest, attacks of shortness of breath
(SoB) following strenuous activity, SoB at rest, or SoB at night time) or at
least one attack of asthma or use of medicines because of breathing problems
in the past 12 months, at the clinical interview. According to the 2002 GINA
guidelines, asthma severity was classified as "intermittent" or "persistent"
considering a composite classification of clinical severity and daily medication
regimen (Figure 13.2) [96,97]. In particular, clinical severity was subdivided
into four increasing steps according to the frequency of diurnal/nocturnal
symptoms in the past 3 months and to FEV1% predicted, the FEV1 value
of a patient divided by the average FEV1 in the population for any person
of the same age, sex and height (step 1: rare symptoms and FEV1>=80%
predicted; step 2: occasional symptoms and FEV1>=80% predicted; step
3: frequent symptoms and 60%<FEV1<80% predicted; step 4: continuous
symptoms and FEV1<60% predicted). Daily medication regimen was sub-
divided into four increasing steps according to the reported daily use in the
past 3 months (step 1: no controller; step 2: low-dose inhaled corticosteroid
[ICS], leukotriene modifier, theophylline, or cromones; step 3: low/medium-
dose ICS combined with long acting beta-2-agonists [LABA], or medium
dose ICS combined with leukotriene modifier or theophylline, or high-dose
ICS alone; step 4: high-dose ICS combined with LABA or with leukotriene
modifier). The subjects who had reported to have used oral steroids either
in short courses or continuously in the past 12 months were classified in the
step 4 of treatment. Finally, the level of asthma severity was defined by
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combining the two independent classifications of clinical severity and daily
medication regimen (intermittent: step 1 of both clinical severity and daily
medication regimen; persistent: all the other combinations). In addition, the
subjects who had reported at least one night spent in a hospital or at least
one Emergency Department (ED) visit in the past 12 months were classified
as persistent asthmatics.
The asthmatic subjects were further classified according to the level of
asthma control using the GINA guidelines, version 2006 [39]. The compo-
nents of asthma control were clustered into two groups:
Group 1:
• asthma attacks (at least one in the last 3 months) and/or daytime
symptoms (at least once a week in the last 3 months)
• nocturnal symptoms (at least one in the last 3 months)
• activity limitations (at least 4 working days lost/days with impaired
daily life activities because of asthma, wheezing or shortness of breath
in the last 12 months)
• reliever treatment (short acting beta2-agonists used more than twice a
week in the last 3 months) and/or rescue treatment (oral steroids used
in the last 12 months)
• FEV1 <80% predicted
Group 2:
• hospitalizations and/or ED visits due to breathing problems (at least
one in the last 12 months)
• oral steroids (daily use or short courses in the last 12 months)
37
• asthma attacks (more than 12 in the last 3 months)
The patients with asthma were defined "controlled" if they had reported no
component from both group 1 and group 2, "partially controlled" if they had
reported 1 or 2 components from group 1 but no component from group 2,
"uncontrolled" if they reported >=3 components from group 1 or at least
1 component from group 2. A "disease status" variable was defined as fol-
lows: "persistent uncontrolled" (i.e. subjects with a persistent uncontrolled
asthma), "persistent controlled/partially controlled" (i.e. subjects with a
persistent controlled or partially controlled asthma), "intermittent" (sub-
jects with an intermittent asthma)
COPD.
The COPD patients were those without asthma who had post-bronchodilator
FEV1/FVC below the lower limit of normal (LLN; according to the Quanjer’s
equations [98]). The best values of FEV1 and FVC were selected based on
up to five technically acceptable manoeuvres.
Chronic bronchitis.
The subjects with chronic bronchitis were those who had reported cough
and/or phlegm episodes for more than three months a year and for at least
two consecutive years at the clinical interview, and who did not have either
asthma or COPD.
7.1.3 Cost estimation
During the clinical interview, all subjects provided detailed information
on the direct healthcare costs (number of specialist and general practitioner
visits, type and number of laboratory tests, medication regimen, type of
vaccinations, number of ED visits and nights spent in a hospital per type
of ward and diagnosis) and on the indirect costs (premature retirement,
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number of lost working days and number of days with limited, not work-
related activities, such as looking after children, housework or studying) due
to their breathing problems in the past 12 months. The number of doses
of each drug consumed was collected for the previous 3-month period and
was multiplied by 4 on the assumption that drug consumption in the past
3 months was representative of the entire year. The information on oral
steroids was collected for the previous 12-month period.
The monetary unit value of each cost component (Table 12.1) was cal-
culated in Euro on the basis of rates, wages and prices in 2013 obtained
at the national level from official sources in 9 European countries (Esto-
nia, France, Germany, Iceland, Italy, Norway, Sweden, Switzerland and
the United Kingdom) (listed in the Appendix). When the national mon-
etary values were not available for the reference year, they were converted
to the 2013 figures using the corresponding Harmonized Indices of Con-
sumer Prices (HICPs) as annual average inflation rates (Eurostat, http:
//epp.eurostat.ec.europa.eu). Due to the variability of the monetary fig-
ures among the ECRHS countries and to the differences among their health
systems, the monetary unit value of each cost component was computed as
the median of the national figures and adjusted for the purchasing power
parity (PPP).
The economic evaluation was carried out from the societal perspective
and the cost components were estimated following the bottom-up approach,
by multiplying the number of times each patient resorted to healthcare ser-
vices, the number of doses of each drug consumed, the number of lost work-
ing days and the number of days with limited, not work-related activities
reported by each subject, by their proper monetary unit value (Table 12.1).
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7.1.4 Statistical analysis
The mean annual cost per patient (with the 95% confidence interval
[95%CI]) was provided for each cost component. Confidence limits were
computed by the bias-corrected and accelerated bootstrap method [99] con-
sidering 20,000 replications. In order to minimize information losses due to
missing values, the mean total cost per patient was obtained by summing up
the estimates of all the cost components.
Multivariable analyses of the association among the individual total cost
(computed as the sum of the available cost components for each subject,
rounded to the nearest integer) for each disease (asthma, COPD and chronic
bronchitis) and a set of potential determinants were performed by using 2-
level random-intercept negative binomial regression models (subject: level 1
unit; centre: level 2 unit). This type of model was chosen for modelling the
overdispersed count data and the hierarchical structure of the ECRHS data.
The following potential determinants were included in the different models:
- cost of asthma: gender, age (5-year increase), body mass index (1-unit
increase), smoking habits (past/current vs never smoking), disease status
(persistent uncontrolled vs intermittent; persistent controlled vs intermit-
tent), age at onset (>=20 vs 0-9 years; 10-19 vs 0-9 years), coexistence with
chronic bronchitis;
- cost of COPD: gender, age, body mass index, smoking habits, coexistence
with chronic bronchitis;
- cost of chronic bronchitis: gender, age, body mass index, smoking habits,
coexistence of comorbidities (presence of at least one of the following: stroke,
angina, heart attack, heart failure, coronary heart disease, hypertension,
arythmia, gastritis, gastric ulcers, gastro-oesophagel reflux, hiatus hernia,
oesophagitis, Crohn’s disease, type 1 and 2 diabetes, hypothyroidism, sleep
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apnea syndrome, pulmonary embolism, osteoporosis, migraine and depres-
sion), coexistence with allergic rhinitis.
The results of the multilevel negative binomial regressions were summarized
as incidence rate ratios with the 95% confidence interval (CI).
The statistical analyses were performed using STATA software, release
15.1 (StataCorp, College Station, Texas, USA) and the R statistical software
(version 3.5.0).
7.2 Results
7.2.1 Main characteristics of the subjects
Out of the 781 asthmatic subjects included in the analysis, 46% had
an intermittent asthma, 31% had a persistent controlled/partially controlled
asthma and 23% had a persistent uncontrolled asthma (Table 12.2). The
intermittent asthmatics were on average younger than the patients with per-
sistent asthma. In addition, the subjects with uncontrolled asthma had a
median BMI of 28.4 and 49% of them reported chronic cough or phlegm..
The COPD sample was mainly represented by individuals with a mild/
moderate disease (96%) (Table 12.3). These patients had a median BMI of
26.1 (IQR: 23.1-29.6) and were more often current or past smokers (82%).
About one COPD patient out of four reported the coexistence of chronic
cough or phlegm.
More than sixty percent of subjects with chronic bronchitis reported co-
existing comorbidities (Table 12.4). These patients were older on average
(p-value<0.0001) and had a higher BMI (median: 27.6) than the subjects
without comorbidities (p-value <0.001).
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7.2.2 Cost of the diseases
Asthma
The mean annual cost per patient increased as the degree of disease
control decreased, ranging from EUR 143 (95%CI: 94-204) and EUR 398
(95%CI: 345-457) for the subjects with an intermittent and a persistent
controlled/partially controlled asthma, respectively, to EUR 5,050 (95%CI:
3,296-6,275) for the subjects with a persistent uncontrolled disease (Ta-
bles 12.5-12.7). The distribution of the cost components differed accord-
ing to the disease status (Figure 13.3). Among the intermittent asthmatics,
the direct medical costs represented 41% of the total cost generated by the
disease (EUR 58), whereas the remaining 59% was due to the indirect non-
medical costs (EUR 85). These figures were 95% (EUR 380) and 5% (EUR
18) for the patients with a persistent controlled/partially controlled asthma,
and 20% (EUR 992) and 80% (EUR 4,058) for the patients with a persistent
uncontrolled disease, respectively. In addition, in the patients with persis-
tent asthma, drug costs accounted for 82% and 8% of the total cost when the
disease was controlled/partially controlled and uncontrolled respectively. In
the latter group of patients, hospital costs represented 9% of the individual
burden.
At the multivariable analysis, in patients with asthma, the lack of control
of a persistent disease was the strongest determinant of the individual total
cost, which was about 27-fold higher compared to the cost of an intermit-
tent asthma (IRR=26.80, 95% CI: 16.82-42.69) after adjusting for the effect
of the other potential predictors (Table 12.8). The individual annual cost
significantly increased (IRR=1.56, 95% CI: 1.07-2.28) with the coexistence
of chronic cough or phlegm and with age (5-year increase: IRR=1.18, 95%
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CI: 1.04-1.34). Predictive margins were EUR 166 [95% CI: 115;217], EUR
456 [95% CI: 282;631] and EUR 4,446 [95% CI: 2,720;6,171] for intermittent,
controlled and uncontrolled asthma, respectively.
COPD
In the patients with COPD, the mean annual cost was EUR 694 (95%CI:
198-1,253) (Table 12.9). Most of the cost (80%) was represented by indirect
nonmedical costs followed by drugs (10%), hospital services (7%) and doctor
visits/laboratory tests (3%) costs (Figure 13.3). At the multivariable analy-
sis, the individual annual cost significantly increased (IRR=17.10, 95% CI:
3.04-96.22) with the coexistence of chronic bronchitis (Table 12.10).
Chronic bronchitis
In the patients with chronic bronchitis, the mean annual cost largely
increased from EUR 94 (95%CI: 38-166) to EUR 642 (95%CI: 249-1,131)
according to the presence of comorbidities (Tables 12.11 and 12.12). The
total cost was mainly driven by the indirect nonmedical costs and the dis-
tribution of the other cost components differed according to the presence or
absence of comorbidities (Figure 13.3). Indeed, as compared to the patients
without comorbidities, those who reported the coexistence of other diseases
showed an increase in hospital costs but decreasing costs due to doctor vis-
its/laboratory tests and drug utilization. After adjusting for the effect of
the other potential predictors, the individual total cost was more than 3-fold
higher among patients with comorbidities compared with those with only
chronic bronchitis (IRR=2.88, 95% CI: 1.10-7.55). In addition, the indi-
vidual total cost significantly increased with the presence of allergic rhinitis
(IRR=3.50, 95% CI: 1.37-8.91) and with age (5-year increase: IRR=1.70,
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95% CI: 1.20-2.39) (Table 12.13). The predictive margins were EUR 198
[95% CI: -23;418] and EUR 570 [95% CI: 125;1,015] for chronic bronchitis
without and with comorbidities, respectively.
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Chapter 8
Study 2: Cost variations of
asthma over ten years
8.1 Methods
8.1.1 Study participants
The present study included the subjects aged 29-56 years at the ECRHS
II, who had been recruited from 25 study centres in 11 countries (Bel-
gium, Estonia, France, Germany, Iceland, Italy, Norway, Spain, Sweden,
Switzerland and the United Kingdom) and who had been identified as hav-
ing physician-diagnosed current asthma at both the ECRHS II and ECRHS
III. Only the 410 asthmatics with complete information on their disease sta-
tus and with information on the cost components due to their illness at both
examinations were included in the present analysis (Figure 13.4).
8.1.2 Definitions
The current asthmatics were those who had reported a physician diagno-
sis of asthma during their life and at least one respiratory symptom (wheez-
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ing, nocturnal tightness in the chest, attacks of SoB following strenuous
activity, SoB at rest, or SoB at night time) or at least one attack of asthma
or use of medicines because of breathing problems in the past 12 months,
at the clinical interview. These patients were further classified according
to their "disease status" as in the Study 1 ("intermittent", "persistent con-
trolled/partially controlled" and "persistent uncontrolled"; see Section 7.1.2)
[38,96] at both the ECRHS II and ECRHS III. The asthmatic patients were
categorised into three different groups according to the variation in their
disease status from the ECRHS II to the ECRHS III:
- "intermittent": intermittent asthma at both the ECRHS II and ECRHS
III;
- "improved": (i) persistent uncontrolled asthma at the ECRHS II and in-
termittent asthma at the ECRHS III; (ii) persistent uncontrolled asthma
at the ECRHS II and persistent controlled/partially controlled asthma at
the ECRHS III; (iii) persistent controlled/partially controlled asthma at the
ECRHS II and intermittent asthma at the ECRHS III; (iv) persistent con-
trolled/partially controlled asthma at both the ECRHS II and ECRHS III;
- "worsened": (i) intermittent asthma at the ECRHS II and persistent
controlled/partially controlled asthma at the ECRHS III; (ii) intermittent
asthma at the ECRHS II and persistent uncontrolled asthma at the ECRHS
III; (iii) persistent controlled/partially controlled asthma at the ECRHS II
and persistent uncontrolled asthma at the ECRHS III; (iv) persistent un-
controlled asthma at both the ECRHS II and ECRHS III.
8.1.3 Cost estimation
The asthmatic subjects provided detailed information on the direct health-
care costs and the indirect costs due to their breathing problems in the past
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12 months (see Section 7.1.3) at both the ECRHS II and ECRHS III. The
monetary unit value of each cost component (Table 12.14) was calculated
in Euro on the basis of rates, wages and prices in 2013 obtained at the na-
tional level from the official sources in 9 European countries (Estonia, France,
Germany, Iceland, Italy, Norway, Sweden, Switzerland and the United King-
dom) and used for the Study 1 (listed in the Appendix). The monetary unit
values obtained for the reference year (2013) were used for quantifying the
economic costs at both the ECRHS II and ECRHS III. The economic evalu-
ation was carried out from the societal perspective and the cost components
were estimated following the bottom-up approach, as described in the Study
1.
8.1.4 Statistical analysis
The mean annual cost per patient was estimated for those components
available at both the ECRHS II and ECRHS III (Table 12.14), and the
individual total cost was calculated at both the examinations. The 10-year
variation in the mean annual cost per patient according to the change in the
subject’s disease status ("intermittent", "improved" and "worsened") was
computed as the difference between the individual costs at the ECRHS II
and at the ECRHS III. Cost variations were estimated by using a 2-level
random-intercept Laplace quantile regression model (subject: level 1 unit;
centre: level 2 unit), adjusting for the effect of sex, age, ever smoking and
low socio-economic status. The statistical analyses were performed using
STATA software, release 15.1 (StataCorp, College Station, Texas, USA) and
the R statistical software (version 3.5.0).
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8.2 Results
Thirty percent of our sample was represented by intermittent asthmatics
at both the examinations (n=128), whilst 33% (n=136) and 36% (n=146)
of the subjects reported an improved and a worsened disease status after a
10-year period, respectively. The group of patients with a worsened disease
status showed a higher percentage of subjects with chronic cough or phlegm
at the ECRHS II (37%), as compared with the intermittent (16%) and the
improved (22%) patients (Table 12.15).
In the "intermittent" group, the mean annual cost per patient at the
ECRHS II (EUR 166; 95%CI: 107-227) was similar to the value observed
at the ECRHS III (EUR 157; 95%CI: 70-292) (Table 12.16). The indirect
costs accounted for about 73% of the total cost at both the examinations,
whereas the contribution of drug costs to the whole burden increased from
9% to 17% (Figure 13.5).
In the "improved" group, the mean annual cost per patient decreased
from EUR 1,058 (95%CI: 752-1,423) at the ECRHS II to EUR 308 (95%CI:
227-405) at the ECRHS III (Table 12.17). Moreover, the distribution of
the cost components was largely different at the two examinations: at the
ECRHS II, the indirect costs were the main cost driver of the total cost
(50%) and the hospitalizations costs accounted for 16%; at the ECRHS III,
67% of the total cost was due to pharmacological treatment (Figure 13.5).
In the "worsened" group, the mean annual cost per patient increased
from EUR 2,137 (95%CI: 935-3,753) at the ECRHS II to EUR 4,023 (95%CI:
2,419-5,530) at the ECRHS III (Table 12.18). The avoidable costs (indirect
nonmedical costs and the costs due to hospital services) accounted for about
87% of the total costs, even if hospital costs at the ECRHS II are due to the
presence of a single patient with a high number of nights spent in a hospital
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(Figure 13.5).
At the multivariable analysis, after adjusting for a set of potential con-
founders, the patients with an improved or worsened asthma from the ECRHS
II to the ECRHS III showed reduced [-145 (95%CI: -275;-15) EUR; p-value=0.029]
and increased [185 (95%CI: 59;311) EUR; p-value=0.005] mean annual costs,
respectively, compared to the patients with an intermittent disease status at




In recent years, literature on the socioeconomic burden of common chronic
respiratory diseases, in particular asthma and COPD, has multiplied in in-
dustrialized countries, pointing out that these disorders place a huge burden
on society not only in terms of disability and premature mortality, but also
in terms of the direct costs due to the use of health services and the indirect
costs due to productivity losses and leisure time forgone. Nevertheless, there
are major gaps in cost estimates in literature, as very few COI analyses on
these diseases have been carried out at an international level in the general
European population. In addition, few COI studies have evaluated both
direct and indirect costs and have estimated the socioeconomic impact of
asthma according to the level of disease severity and control. Furthermore,
there is few information on the socioeconomic burden of chronic bronchitis,
also in relation with the presence of comorbidities, and on the change over
time in asthma costs. This thesis aimed at investigating these mentioned
areas of concern.
The main findings from these two studies on patients identified in the general
European population are:
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Asthma: (i) the economic cost was impressive in subjects with persistent
uncontrolled asthma; (ii) in this group of patients, the individual total cost
was largely driven by indirect non-medical costs; (iii) the individual total
cost was increased by coexisting chronic cough or phlegm; (iv) the mean
annual cost per patient significantly increased/decreased when the disease
status worsened/improved over 10 years.
COPD: the mean annual cost per patient was not negligible even in patients
with a mild/moderate form of the disease.
Chronic bronchitis: the mean annual cost per patient was high only when
comorbidities were present.
Compared to the patients with an intermittent or a controlled/partially
controlled persistent asthma, those with an uncontrolled persistent disease
showed an impressively higher annual total cost. After adjusting for a set
of potential confounding variables, the disease status was the main determi-
nant of the individual total cost among adult asthmatics in Europe. Since
uncontrolled persistent asthmatics are not a negligible group of subjects (23%
of the individuals in our sample), this result points out that the economic
burden of asthma could be largely reduced by proper management of these
high-cost patients. These findings are in accordance with the results ob-
tained in previous COI studies in different countries [46,52,58,100], in which
poor asthma control was associated with an increase in socio-economic costs.
However, most studies in literature reported estimates of the asthma costs
across the levels of disease control without adjusting for the effect of con-
founding factors.
In the uncontrolled/persistent patients, the main determinant of the eco-
nomic cost was represented by the indirect non-medical costs, which largely
exceeded the direct medical expenditures. Given that asthma also affect
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young adults, the contribution of productivity losses to the total cost can
be substantial. This result is consistent with other studies [46,52], which
demonstrated that the loss of productivity is the largest component of the
total cost in Europe. Unfortunately, the majority of the studies fail to con-
sider the contribution of premature retirement and leisure time forgone to
the indirect costs, which instead was addressed in this thesis. High indirect
costs highlight the great impact of asthma on individuals and families, be-
cause these costs also reflect the functioning and quality of life of patients in
the presence of the disease [101]. Since indirect costs only occur when the
disease has become sufficiently intrusive to interfere with a patient’s lifestyle
[102], the results of this thesis provide further evidence that asthma is a
substantial burden for both the individual and society in Europe.
In agreement with other economic evaluations [46,58,103], medications costs
were the largest driver of the direct medical expenditures, in particular
among the persistent controlled/partially controlled asthmatics. It is known
that out-patient and in-patient care are the largest component of direct costs
in developing regions, while therapy costs are the main drivers in richer coun-
tries where there is a higher access to control medications. Good control
achieved by adequate therapy could prevent encounters with the health care
system and could reduce indirect costs. Accordingly, we found that the per-
sistent/uncontrolled patients were characterized by a lower expenditure for
medication and by higher costs due to hospital services and loss of produc-
tivity than better controlled patients.
Higher costs were reported by the asthmatics with coexisting chronic cough
or phlegm. This result is consistent with the findings of previous COI studies
and suggests that these subjects could have a poorer level of disease control
[104] and/or a more severe form of asthma [105]. Indeed, since it is known
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that chronic cough or phlegm significantly increases the risk of developing
COPD in adult subjects regardless of smoking habits [68], the asthmatic pa-
tients with this symptom could have higher costs because of the coexistence
of asthma and chronic obstructive pulmonary disease [106].
In the asthmatic patients, the mean annual cost significantly increased or de-
creased over a 10-year period when the disease status worsened or improved,
respectively. This positive association was also confirmed after adjusting
for a set of potential confounding variables, such as the socio-economic sta-
tus. Most studies in literature reported a simple difference in the costs of
asthma across the control levels completely ignoring the effect of confound-
ing factors. Compared to the patients who reported a worsened disease
status, those who had an improvement showed a significant increase in drug
costs and a substantial decrease in the indirect non-medical costs and in
the hospital services burden. The achievement of a proper asthma man-
agement can permit to control the disease in the majority of patients with
substantial cost savings from both the individual and societal perspectives,
since the costs of uncontrolled asthma far outweigh the additional costs of
the control measures. This relationship might reflect the fact that patients
whose asthma is controlled require less medication and incur fewer costs,
and it is consistent with the results from prospective trials and initiatives
aimed at increasing the use of controller treatment to achieve higher levels
of control and to avoid exacerbations [107-110]. Indeed, while some patients
might be relatively refractory to controllers and require costly maintenance
treatment without reaching satisfactory levels of control [53], the majority
of asthmatic subjects can achieve control with doses of treatment that are
affordable in most health systems. Therefore, the potential reduction in the
costs of asthma when an individual moves from the uncontrolled to the con-
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trolled state can be considered a preventable source of burden for both the
society and individuals.
The main strength of this thesis was to consider general population samples
rather than clinically selected groups. While this approach made it possible
to provide a real-world assessment of the economic impact of asthma, COPD
and chronic bronchitis among adults in Europe, on the other hand it allowed
to obtain very limited data on the cost of severe COPD. In spite of this,
these findings showed that the mean annual cost per COPD patient was not
negligible even in subjects with a mild/moderate form of the disease.
Overall, the prevalence of mild and moderate COPD is greater than the
prevalence of severe and very severe COPD, but a not appropriate therapy
in this group of patients could increase the total socioeconomic burden of this
population [14]. Accordingly, the results of this thesis showed that patients
with mild/moderate COPD were characterized by a relatively low expendi-
ture for medication and very high indirect costs. Therefore, a more appro-
priate use of medications to treat COPD, particularly in the early stages of
the disease, may reduce COPD-related complications and the overall burden
of the disease. In addition, due to the fact that COPD is a heterogeneous
disease, more research is required to understand the characteristics of each
patient to provide the best individualised intervention.
So far, this is the first study that evaluated the cost of chronic bronchitis in
patients who did not have either asthma or COPD, taking into account the
impact of coexisting comorbidities on the total cost. In patients with chronic
bronchitis, the total cost was mainly driven by the indirect non-medical costs
and the distribution of the other cost components differed according to the
presence of comorbidities. After adjusting for the effect of the other potential
predictors, the individual total cost was more than 3-fold higher among pa-
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tients with comorbidities compared with those with only chronic bronchitis
and it was characterized by a four-fold increase in hospital costs. In subjects
with chronic bronchitis, these results highlighted the important contribution
of comorbidities to the total cost. Therefore, strategies for the prevention,
diagnosis, and effective management of comorbidities would also decrease
the overall financial burden associated with chronic bronchitis and should be
promoted in future health economic evaluations of the disease.
Due to complexity and heterogeneity of human diseases, it may be very
difficult to transform their possible interconnectedness with multimorbidities
into economic models. However, as stated by Barabasi et al. [111], it would
be difficult if not counter-intuitive to consider human diseases as invariably
independent. Therefore, the pressure for including comorbidities in the eval-
uation of economic interventions seems to mount. Both systems biology and
network medicine (linking disease phenotypic features with known disease
genes or with protein interactions) are currently giving rise to new ways for
understanding the interconnectedness of multimorbidities that may also en-
able more accurate health economic evaluations in the future.
In conclusion, the economic cost of asthma, COPD and chronic bronchitis
is high in Europe also among patients from the general population. The
cost of asthma significantly increases with the lack of disease control in pa-
tients with a persistent disease and with the coexistence of chronic cough
or phlegm. The individual total cost is high in subjects with COPD and
chronic bronchitis according to the presence of chronic cough or phlegm and
comorbidities, respectively.
In the challenging context of health care systems, which are dynamically
influenced by many factors (e.g. the emergence of new treatments, the up-
date of disease guidelines, the change in demographics and in environmen-
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tal/behavioral risk factors), decision makers need to make sound decisions on
how to spend constrained resources to maximise population health. There-
fore, up-to-date estimates of the socio-economic burden of diseases can help
in informing resource allocations. COl studies can provide such estimates
that are policy-relevant and can be used in combination with other informa-
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Estonia
Ministry of Social Affairs; Estonian Health Insurance Health Services List
https://www.riigiteataja.ee/akt/123022013001 [doctor visits, clinical
and laboratory tests, ED visits, hospital admissions]. Estonian State Agency
of medicines http://www.sam.ee/ [pharmacological treatment, antibiotics,
vaccinations, other vaccinations]. Statistical Office of Estonia http://www.
stat.ee/67065 [productivity losses, leisure time forgone].
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Vidal drug compendium. 99th edition. OVP Edition, Paris [pharmacolog-
ical treatment, antibiotics, vaccinations, other vaccinations]. Nomenclature
Generale des Actes Professionnels, Union Nationale des Caisses de Securite
Sociale, Paris [doctor visits]. Nomenclature des Actes de Biologie Medicale,
site de l’Assurance Maladie http://www.ameli.fr [clinical and laboratory
tests]. Assistance Publique des Hopitaux de Paris (APHP), Direction des Fi-
nances; Groupes homogenes de sejours (GHS) (diagnosis-related stays) [ED
visits, hospital admissions]. Institut national de la statistique et des etudes
71
economiques (INSEE), France, http://www.insee.fr; Action Medicale et
Sociale e Domicilie (AMSD) Paris [productivity losses, leisure time forgone].
Germany
Betriebskrankenkasse, Landesvertretung Bayern; Krauth C et al. Empirical
standard costs for health economic evaluation in Germany - a proposal by the
working group methods in health economic evaluation. Gesundheitswesen.
2005;67(10):736-46. Updated to 2012 using the rate of change in physician re-
imbursement per case according to the KBV (National Association of Statu-
tory Health Insurance Physicians) [clinical and laboratory tests, doctor visits,
ED visits]. Betriebskrankenkasse-Bavaria http://www.bkk-lv-bayern.de;
http://www.krankenhaus-aok.de; German diagnose-related groups http:
//www.g-drg.de [hospital admissions]. Wissenschaftliches Institut der All-
gemeine Ortskrankenkasse http://www.wido.de [pharmacological treatment,
antibiotics, vaccinations, other vaccinations]. Federal Statistical Office of
Germany https://www.destatis.de/DE/Startseite.html [productivity losses,
leisure time forgone].
Iceland
Agreement between Medical Association in Iceland and The State Social
Security Institute and cost figures from Reykjavik Primary Health Care Ser-
vices, Department of Administration [doctor visits]. Agreement between
Medical Association in Iceland and The State Social Security Institute [clin-
ical and laboratory tests]. Icelandic Medicines Agency https://www.ima.is
[pharmacological treatment]. Landspitali University Hospital, Department
of Information and Finance [ED visits, hospital admissions]. Hagstofa Is-
lands (Institute of Icelandic Economy). Reykjavik homeservice. Institute




Prontuario Servizio Sanitario Nazionale [pharmacological treatment, antibi-
otics, vaccinations, other vaccinations]. Tariffario regionale Regione Lom-
bardia [clinical and laboratory tests, doctor visits, ED visits]. Ministero
della salute - Tariffario Unico Nazionale 2009 [hospital admissions]. Istituto
Nazionale di Statistica http://www.istat.it; Federazione Italiana Lavora-
tori Commercio Alberghi Mense e Servizi - Confederazione Generale Italiana
del Lavoro (FILCAMS-CGIL) http://www.filcams.cgil.it [productivity
losses, leisure time forgone]
Norway
Costs supplied by the Norwegian Pharmacy Association by a list of maximum
prices set by the Norwegian Medicines Agency [pharmacological treatment].
Vegard HÃěvik Senior Advisor at the The Norwegian Directorate of Health
[doctor visits, ED visits]. Haukeland University Hospital, Bergen, Norway
[clinical and laboratory tests, hospital admissions]. Statistics Norway, Oslo
[productivity losses, leisure time forgone].
Sweden
FASS, Swedish Association of the Pharmaceutical Industry http://www.
fass.se and Uppsala County Council [pharmacological treatment, antibi-
otics, vaccinations, other vaccinations]. Uppsala County Council [doctor vis-
its, clinical and laboratory tests, ED visits, hospital admissions]. Statistics
Sweden, Stockholm http://www.scb.se [productivity losses, leisure time
forgone].
Switzerland
Swiss Compendium of Medication [pharmacological treatment]. Swiss Med-
ical Tariff (TARMED) [doctor visits, clinical laboratory tests, ED visits,
hospital admissions]. Swiss Federal Office of Statistics and International
73
Labour Organization - Database of Conditions of Work and Employment
Laws [productivity losses, leisure time forgone].
The United Kingdom
NHS Electronic Drug Tariff [pharmacological treatment, antibiotics]. Na-
tional Institute for Health and Care Excellence [vaccinations]. Flu immu-
nization programme of the Department of Health and National Institute
for Health and Care Excellence on the basis of the information reported in
the British National Formulary [other vaccinations]. Department of Health
[ED visits]. Department of Health - National Schedule of Reference Costs
(Year: 2013-14) [hospital admissions]. Personal Social Services Research
Unit (PSSRU) [doctor visits]. NHS Foundation Trust [clinical and laboratory
tests]. Office for National Statistics - Annual Survey of Hours and Earnings


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chronic cough or phlegm (%)2 25.6
Allergic rhinitis (%)3 17.1
sd: standard deviation; BMI: body mass index; IQR: in-
terquartile range. 1. Subjects were considered smokers -
current or past- if they had reported having smoked at least
20 packs of cigarettes or 360 grams of tobacco in their life-
time, or at least one cigarette per day or one cigar a week
for one year. 2. Having reported cough and/or phlegm from
the chest, usually in winter and on most days for as long as































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 13.2: Classification of asthma severity according to the GINA guidelines.
Composite classification of asthma severity over the last 3 months based on the
clinical severity on current treatment and on the treatment classification according
to the GINA. Step 1 = No daily controller; Step 2 = low-dose inhaled corticosteroid
(ICS), leukotriene modifier, theophylline or cromones; Step 3 = low/medium-dose
ICS combined with long-acting beta2-agonists (LABA), or medium dose ICS com-
bined with leukotriene modifier or theophylline, or high-dose ICS alone; Step 4 =
high-dose ICS combined with LABA or with leukotriene modifier. The subjects
who reported they had used oral steroids either in short courses or continuously in






































































































































































































































































































Figure 13.4: Flow-chart of the subjects included in Study 2.
 
1,241 current asthmatics at ECRHS II 
562 current asthmatics at ECRHS II & 
ECRHS III 
679 individuals excluded: non current 
asthmatics in ECRHS III 
57 individuals excluded:missing data 
on the cost components 
410 individuals included in the analysis 
95 individuals excluded: missing data 
on disease severity and/or control 
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